Ruxolitinib in GvHD (RIG) study: A multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
Nikolas Von Bubnoff*, Gabriele Ihorst, Olga Grishina, Nadine Röthling, Hartmut Bertz, Justus Duyster, Jürgen Finke, Robert Zeiser
Dive into the research topics of 'Ruxolitinib in GvHD (RIG) study: A multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)'. Together they form a unique fingerprint.